Imperial College London


Faculty of MedicineDepartment of Immunology and Inflammation

Professor of Practice (Chronic Myeloid Malignancies)



+44 (0)20 3313 5038d.milojkovic




Cancer CentreHammersmith Campus






Maynard S, Ros-Soto J, Chaidos A, et al., 2021, The role of ibrutinib in COVID-19 hyperinflammation: a case report, International Journal of Infectious Diseases, Vol:105, ISSN:1201-9712, Pages:274-276

Claudiani S, Apperley JF, Deplano S, et al., 2016, Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia, American Journal of Hematology, Vol:91, ISSN:1096-8652, Pages:E480-E481

Neelakantan P, Rezvani K, May P, et al., 2014, Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects, British Journal of Haematology, Vol:164, ISSN:0007-1048, Pages:608-610

Milojkovic D, Apperley J, 2008, State-of-the-art in the treatment of chronic myeloid leukaemia, Current Opinion in Oncology, Vol:20, ISSN:1040-8746, Pages:112-121

De Melo VA, Milojkovic D, Khorashad JS, et al., 2007, Philadelphia-negative clonal haematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukaemia, Blood, Vol:110, Pages:3086-3087

More Publications